Phase 1 Interim Population PK/PD Modeling and Recommended Phase 2 Dose Exploration for IMM-1-104, A Novel Concept Oral Deep Cyclic Inhibitor of MEK

Immuneering Corporation
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.